Polyganics takes transparent nerve guide to the EU:
This article was originally published in Clinica
Executive Summary
Dutch firm Polyganics has gained EU market clearance for its resorbable and transparent synthetic nerve guide, Neurolac, for repairing peripheral nerve damage. The tube-shaped device is sutured to both ends of the transected nerve and guides the outgrowing nerve in a protective environment, preventing neuroma formation. After the nerve function has been restored, the nerve guide is resorbed by the body. The product's transparency, which the Groningen firm says is a first-of-its-kind in Europe, allows surgeons to see what they are doing and facilitates easy and reliable closure of the nerve gap. Neurolac is already cleared in the US.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.